Data confirms the 10-year screening colonoscopy interval is safe for average-risk adults and can be extended in some subgroups, supporting the possibility of personalized, risk-adapted CRC screening.
Findings from this phase 2 trial support further study of erlotinib as "an effective, acceptable cancer preventive agent for FAP-associated gastrointestinal polyposis," the study team says.
/PRNewswire/ The "Colonoscopy Devices - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com s offering. Global Colonoscopy.